.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Thomas E. Hutson, DO, PharmD, PhD, FACP

Articles

Final Analysis of Lenvatinib + Pembrolizumab vs Sunitinib in Patients With Advanced Renal Cell Carcinoma With or Without Bone Metastases in CLEAR

November 24th 2025

Thomas Hutson, DO, PharmD, PhD, FACP presents the latest findings from the CLEAR trial on lenvatinib + pembrolizumab vs sunitinib in patients with advanced renal cell carcinoma with or without bone metastases.